S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Status: | Recruiting |
---|---|
Conditions: | Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 75 |
Updated: | 4/17/2018 |
Start Date: | October 2015 |
End Date: | October 2021 |
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and
oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and
paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients
with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as
fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and
paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. It is not yet known whether combination chemotherapy is more effective than
gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before
surgery in treating pancreatic cancer.
oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and
paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients
with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as
fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and
paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. It is not yet known whether combination chemotherapy is more effective than
gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before
surgery in treating pancreatic cancer.
PRIMARY OBJECTIVES:
I. To assess 2-year overall survival in each treatment arm (fluorouracil, irinotecan
hydrochloride, and oxaliplatin [modified (m)FOLFIRINOX] and gemcitabine [gemcitabine
hydrochloride]/nab-paclitaxel [paclitaxel albumin-stabilized nanoparticle formulation]) in
patients with resectable pancreatic cancer.
II. If the stated threshold is met in one or both arms: to choose the better regimen with
respect to 2-year overall survival.
SECONDARY OBJECTIVES:
I. To estimate, for all patients and within treatment arms: frequency and severity of adverse
events associated with chemotherapy in the perioperative setting.
II. To estimate, for all patients and within treatment arms: proportion of patients going to
surgery for resection after preoperative chemotherapy.
III. To estimate, for all patients and within treatment arms: proportion of patients
achieving macroscopically complete tumor removal with negative microscopic surgical margins
(R0) resection after preoperative chemotherapy.
IV. To estimate, for all patients and within treatment arms: overall response rate following
preoperative chemotherapy, including confirmed and unconfirmed, complete and partial
response, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
V. To estimate, for all patients and within treatment arms: pathologic response rates after
R0 or macroscopically complete tumor removal with any positive microscopic surgical margin
(R1) resection.
VI. To estimate, for all patients and within treatment arms: patterns of recurrence
(loco-regional, distant) after R0 or R1 resection.
VII. To estimate, for all patients and within treatment arms: disease-free survival from the
time of R0 or R1 resection.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive oxaliplatin intravenously (IV) over 2 hours and irinotecan
hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive fluorouracil IV over
46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence
of disease progression or unacceptable toxicity. Patients achieving stable disease or better
undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8
weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin,
irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or
unacceptable toxicity.
ARM II: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30
minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment
repeats every 28 days for 3 courses in the absence of disease progression or unacceptable
toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after
completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy,
patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle
formulation and gemcitabine hydrochloride treatment in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 2 years.
I. To assess 2-year overall survival in each treatment arm (fluorouracil, irinotecan
hydrochloride, and oxaliplatin [modified (m)FOLFIRINOX] and gemcitabine [gemcitabine
hydrochloride]/nab-paclitaxel [paclitaxel albumin-stabilized nanoparticle formulation]) in
patients with resectable pancreatic cancer.
II. If the stated threshold is met in one or both arms: to choose the better regimen with
respect to 2-year overall survival.
SECONDARY OBJECTIVES:
I. To estimate, for all patients and within treatment arms: frequency and severity of adverse
events associated with chemotherapy in the perioperative setting.
II. To estimate, for all patients and within treatment arms: proportion of patients going to
surgery for resection after preoperative chemotherapy.
III. To estimate, for all patients and within treatment arms: proportion of patients
achieving macroscopically complete tumor removal with negative microscopic surgical margins
(R0) resection after preoperative chemotherapy.
IV. To estimate, for all patients and within treatment arms: overall response rate following
preoperative chemotherapy, including confirmed and unconfirmed, complete and partial
response, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
V. To estimate, for all patients and within treatment arms: pathologic response rates after
R0 or macroscopically complete tumor removal with any positive microscopic surgical margin
(R1) resection.
VI. To estimate, for all patients and within treatment arms: patterns of recurrence
(loco-regional, distant) after R0 or R1 resection.
VII. To estimate, for all patients and within treatment arms: disease-free survival from the
time of R0 or R1 resection.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive oxaliplatin intravenously (IV) over 2 hours and irinotecan
hydrochloride IV over 90 minutes on days 1 and 15. Patients also receive fluorouracil IV over
46 hours on days 1-3 and 15-17. Treatment repeats every 28 days for 3 courses in the absence
of disease progression or unacceptable toxicity. Patients achieving stable disease or better
undergo pancreatectomy 4-8 weeks after completion of first 3 courses of treatment. Within 4-8
weeks following pancreatectomy, patients receive an additional 3 courses of oxaliplatin,
irinotecan hydrochloride, and fluorouracil treatment in the absence of disease progression or
unacceptable toxicity.
ARM II: Patients receive paclitaxel albumin-stabilized nanoparticle formulation IV over 30
minutes and gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15. Treatment
repeats every 28 days for 3 courses in the absence of disease progression or unacceptable
toxicity. Patients achieving stable disease or better undergo pancreatectomy 4-8 weeks after
completion of first 3 courses of treatment. Within 4-8 weeks following pancreatectomy,
patients receive an additional 3 courses of paclitaxel albumin-stabilized nanoparticle
formulation and gemcitabine hydrochloride treatment in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 2 years.
Inclusion Criteria:
- Patients must have histologically or cytologically proven pancreatic adenocarcinoma;
histologies other than adenocarcinoma, or any mixed histologies, will NOT be eligible
- Patients must have measurable disease in the pancreas; computed tomography (CT) scans
or magnetic resonance imaging (MRIs) used to assess measurable disease must have been
completed within 28 days prior to registration; all disease must be assessed and
documented on the baseline tumor assessment form
- Patients must have resectable primary tumor based on contrast-enhanced CT or MRI (CT
or MRI without contrast as part of positron emission tomography [PET]/CT or PET/MRI is
NOT acceptable; CT or MRI with contrast as part of PET/CT or PET/MRI is acceptable) of
the chest, abdomen, and pelvis, where resectable is defined as:
- No involvement of the celiac artery, common hepatic artery, and superior
mesenteric artery (and, if present, replaced right hepatic artery)
- No involvement, or < 180° interface between tumor and vessel wall, of the portal
vein and/or superior mesenteric vein; and patent portal vein/splenic vein
confluence
- No evidence of metastatic disease
- Note: for tumors of the body and tail of the pancreas, involvement of the splenic
artery and vein of any degree is considered resectable disease
- CT scans or MRIs used to assess disease at baseline must be submitted for central
review
- Patients must have surgical consult to verify patient is a surgical candidate within
21 days prior to registration
- Patients must not have received prior surgery, radiation therapy, chemotherapy,
targeted therapy, or any investigational therapy for pancreatic cancer
- Patients must have a Zubrod performance status of 0-1
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 9 g/dL
- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN
- Serum albumin >= 3 g/dL
- Serum creatinine =< IULN within 14 days prior to registration
- Patients with uncontrolled intercurrent illness including, but not limited to ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements will NOT be eligible
- No prior malignancy is allowed except for adequately treated basal (or squamous cell)
skin cancer, in situ cervical cancer, in situ breast (ductal or lobular) cancer, or
other cancer for which the patient has been disease and treatment-free for two years
- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method for up to 3 months after the
final administered dose of chemotherapy; a woman is considered to be of "reproductive
potential" if she has had menses at any time in the preceding 12 consecutive months;
in addition to routine contraceptive methods, "effective contraception" also includes
heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect
of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or
bilateral tubal ligation; however, if at any point a previously celibate patient
chooses to become heterosexually active during the time period for use of
contraceptive measures, he/she is responsible for beginning contraceptive measures
- Sites must seek additional patient consent for the future use of specimens
- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines
- As a part of the OPEN registration process the treating institution's identity is
provided in order to ensure that the current (within 365 days) date of institutional
review board approval for this study has been entered in the system
We found this trial at
803
sites
300 South 6th Avenue
West Reading, Pennsylvania 19611
West Reading, Pennsylvania 19611
(610) 988-8000
Principal Investigator: Terrence P. Cescon
Phone: 610-988-9323
Reading Hospital At Reading Health System, advancing your health and wellness is our mission. When...
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Heloisa P. Soares
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 866-844-9355
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
Burlington, Vermont 05401
802-656-8990
Principal Investigator: Maura M. Barry
Phone: 802-656-4101
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
701 Doctors Dr
Kinston, North Carolina 28504
Kinston, North Carolina 28504
(252) 559-2200
Principal Investigator: Peter R. Watson
Phone: 252-559-2200
Kinston Medical Specialists offers comprehensive medical services for all ages. Whether it’s a case of...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
Rochester, New York 14642
(585) 275-2121
Principal Investigator: Paul M. Barr
Phone: 585-275-5830
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
Principal Investigator: Sukeshi P. Arora
Phone: 210-450-3800
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
Yakima, Washington 98902
Principal Investigator: Gary E. Goodman
Phone: 206-215-3962
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
1 Akron General Ave
Akron, Ohio 44307
Akron, Ohio 44307
(330) 344-6000
Principal Investigator: Esther H. Rehmus
Phone: 330-344-6348
Akron General Medical Center It
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Heloisa P. Soares
Phone: 505-272-0530
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
1111 Duff Ave
Ames, Iowa 50010
Ames, Iowa 50010
(866) 972-5477
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
McFarland Clinic PC-William R Bliss Cancer Center The William R. Bliss Cancer Center at Mary...
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Gary E. Goodman
Phone: 206-215-3962
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Gary E. Goodman
Phone: 206-215-3962
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Mark M. Zalupski
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Harish G. Ahuja
Phone: 877-405-6866
Click here to add this to my saved trials
Antioch, California 94531
Principal Investigator: Tatjana Kolevska
Phone: 510-891-3400
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
Asheboro, North Carolina 27203
(336) 625-5151
Principal Investigator: Vinay K. Gudena
Phone: 336-832-0821
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-213-4150
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Mehmet Akce
Phone: 404-778-1868
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Mehmet Akce
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Atlanta, Georgia 30342
Principal Investigator: Mehmet Akce
Phone: 888-823-5923
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, New York 13021
Principal Investigator: Jeffrey J. Kirshner
Phone: 315-472-7504
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Anthony D. Elias
Phone: 970-297-6150
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Austin, Texas 78731
Principal Investigator: Vivian J. Cline
Phone: 702-384-0013
Click here to add this to my saved trials
Austin, Texas 78705
Principal Investigator: Vivian J. Cline
Phone: 702-384-0013
Click here to add this to my saved trials
Austin, Texas 78745
Principal Investigator: Vivian J. Cline
Phone: 702-384-0013
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 888-221-4849
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Mehmet S. Copur
Phone: 502-350-5700
Click here to add this to my saved trials
Bartlett, Tennessee 38133
Principal Investigator: Stephen W. Behrman
Phone: 901-226-3077
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: Suma P. Satti
Phone: 504-842-3708
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beachwood, Ohio 44122
Principal Investigator: Jennifer R. Eads
Phone: 800-641-2422
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-395-8115
Click here to add this to my saved trials
Bellevue, Washington 98005
Principal Investigator: Gary E. Goodman
Phone: 206-215-3962
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Gary L. Buchschacher
Phone: 626-564-3455
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 614-488-2745
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
1300 Anne Street NW
Bemidji, Minnesota 56601
Bemidji, Minnesota 56601
(218) 751-5430
Principal Investigator: Preston D. Steen
Phone: 712-252-0088
Sanford Clinic North-Bemidgi Sanford Health is a voluntary, not-for-profit health care organization. Through its entities,...
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Berlin, Vermont 05602
Principal Investigator: Maura M. Barry
Phone: 802-656-4101
Click here to add this to my saved trials
Bethlehem, Pennsylvania 18015
Principal Investigator: Darius C. Desai
Phone: 888-823-5923
Click here to add this to my saved trials
Bettendorf, Iowa 52722
Principal Investigator: David M. Spector
Phone: 563-359-9876
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Benjamin T. Marchello
Phone: 800-648-6274
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Birmingham, Alabama 35233
Principal Investigator: Ravi K. Paluri
Phone: 205-934-0309
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 712-252-0088
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Click here to add this to my saved trials
1501 North Oakland Drive
Bolivar, Missouri 65613
Bolivar, Missouri 65613
417-326-7200
Principal Investigator: Jay W. Carlson
Phone: 888-221-4849
Central Care Cancer Center at Carrie J. Babb Cancer Center Cancer treatment often requires a...
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 309-243-3605
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Joseph J. Merchant
Phone: 515-239-2621
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Kevan L. Hartshorn
Phone: 617-638-8265
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 888-221-4849
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Mehmet S. Copur
Phone: 866-844-9355
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 208-367-7954
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-224-5593
Click here to add this to my saved trials
Bristol, Tennessee 37620
Principal Investigator: Asheesh Shipstone
Phone: 423-578-8538
Click here to add this to my saved trials
Bristol, Virginia 24201
Principal Investigator: Asheesh Shipstone
Phone: 423-224-5593
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Lakshmi Rajdev
Phone: 718-904-2730
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Lakshmi Rajdev
Phone: 718-904-2730
Click here to add this to my saved trials
Bronx, New York 10461
Principal Investigator: Lakshmi Rajdev
Phone: 718-904-2730
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Mehmet S. Copur
Phone: 979-774-0808
Click here to add this to my saved trials
130 S Bryn Mawr Ave
Bryn Mawr, Pennsylvania 19010
Bryn Mawr, Pennsylvania 19010
(484) 337-3000
Principal Investigator: Albert S. DeNittis
Phone: 484-476-2649
Bryn Mawr Hospital Bryn Mawr Hospital, a nationally recognized community teaching hospital, is conveniently located...
Click here to add this to my saved trials